Summary

KEY INSIGHTS
CNTX-4975 is currently being evaluated as a treatment for moderate to severe knee osteoarthritis (OA) pain. It is a highly purified, synthetic form of trans-capsaicin administered via injection directly to the pain site. This innovative treatment harnesses capsaicin’s natural analgesic properties, aiming to provide rapid, long-lasting, and targeted pain relief.
CNTX-4975 further works by targeting the TRPV1 receptor, which deactivates local pain fibers that transmit pain signals to the brain. This mechanism can potentially offer pain relief lasting up to six months until the affected pain fibers regenerate. Its precise delivery and selective action allow for effective pain management without affecting other nerve functions.
Developed by Centrexion Therapeutics, CNTX-4975 is part of the company's commitment to addressing unmet needs in chronic pain management through non-opioid, non-addictive treatments. Centrexion Therapeutics, founded in 2013 and headquartered in Boston, focuses on developing a broad pipeline of pain management therapies, including topical gels, joint and deep tissue injections, spinal delivery methods, and three distinct oral therapies.
MARKET POTENTIAL AND POSITIONING
CNTX-4975, the flagship product candidate from Centrexion Therapeutics, is strategically poised in the market as a promising non-opioid therapy for osteoarthritis, specifically for the treatment of moderate to severe knee osteoarthritis (OA) pain. Currently, in Phase III clinical trials, CNTX-4975 introduces a novel approach by using an ultra-pure, synthetic form of trans-capsaicin and TRPV1 receptor agonists delivered directly to the pain site via injection. This targeted delivery method is designed to offer effective, long-lasting pain relief while avoiding the risks commonly associated with opioid treatments.
Moreover, the completion of patient enrollment in the third Phase III trial, VICTORY-3, in September 2019 highlights the company's dedication to optimizing the administration process and improving patient comfort. The VICTORY-3 trial, which includes a single injection per knee in 857 participants, is designed to assess both the efficacy and safety of a 1.0 mg dose of CNTX-4975 in patients experiencing chronic, moderate to severe knee OA pain.
REGIONAL ANALYSIS
Inkwood Research offers an analysis of seven key markets:
• United States
• Germany
o In Germany, the growing elderly population and rising obesity rates are key factors driving the increasing prevalence of osteoarthritis, particularly in weight-bearing joints such as the knees and hips. This condition places a significant strain on the healthcare system, creating a strong demand for medical treatments, knee osteoarthritis rehabilitation services, and joint replacement surgeries.
o According to industry sources, in 2023, there were 18.89 million individuals in Germany aged 65 years or older. Knee and hip joints are most frequently impacted, resulting in considerable pain, stiffness, and decreased mobility.
• France
• United Kingdom
• Italy
• Spain
• Japan

ページTOPに戻る

Table of Contents

TABLE OF CONTENTS
1. INTRODUCTION TO THE REPORT
2. CNTX-4975 OVERVIEW
2.1. PRODUCT DETAIL
2.2. CLINICAL DEVELOPMENT
2.2.1. CLINICAL STUDIES
2.2.2. CLINICAL TRIALS INFORMATION
2.2.3. SAFETY AND EFFICACY
2.3. OTHER DEVELOPMENTAL ACTIVITIES
2.4. PRODUCT PROFILE
3. COMPETITIVE LANDSCAPE
3.1. MARKETED THERAPIES
3.2. LATE-STAGE EMERGING THERAPIES
4. CNTX-4975 MARKET ASSESSMENT
4.1. MARKET OUTLOOK OF CNTX-4975 IN OSTEOARTHRITIS
5. 7 MAJOR MARKET’S ANALYSIS
5.1. MARKET SIZE OF CNTX-4975 IN THE 7 MAJOR MARKETS FOR OSTEOARTHRITIS
5.2. 7 COUNTRY ANALYSIS
5.2.1. MARKET SIZE OF CNTX-4975 IN UNITED STATES FOR OSTEOARTHRITIS
5.2.2. MARKET SIZE OF CNTX-4975 IN GERMANY FOR OSTEOARTHRITIS
5.2.3. MARKET SIZE OF CNTX-4975 IN FRANCE FOR OSTEOARTHRITIS
5.2.4. MARKET SIZE OF CNTX-4975 IN ITALY FOR OSTEOARTHRITIS
5.2.5. MARKET SIZE OF CNTX-4975 IN SPAIN FOR OSTEOARTHRITIS
5.2.6. MARKET SIZE OF CNTX-4975 IN UNITED KINGDOM FOR OSTEOARTHRITIS
5.2.7. MARKET SIZE OF CNTX-4975 IN JAPAN FOR OSTEOARTHRITIS
6. SWOT ANALYSIS
7. ANALYST PERSPECTIVE